May 15, 2026 · PDUFA decision
VSTM PDUFA decision: a negative outcome, -8.3%
On May 15, 2026, avutometinib (VS-6766) — Verastem, Inc. (Low Grade Ovarian Serous Adenocarcinoma) reached its PDUFA decision. The result was a negative outcome, and the stock moved -8.3% in the window around the event. It had already run -26.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$4.71
1d before
$4.32
Event day
$4.32
1d after
$4.13
5d after
Pre-catalyst setup
-26.9%
30-day run-up
7022%
30-day volatility
0.7×
volume spike